Ariad Pharmaceuticals (Nasdaq: ARIA) has named Paris Panayiotopoulos president and chief executive officer, effective January 1, 2016.
Mr Panayiotopoulos will succeed Harvey Berger, the founder, chairman and chief executive of Ariad. Mr Panayiotopoulos joins Ariad from his current position of president of EMD Serono. Prior to this, he was at US drug major Eli Lilly & Co (NYSE: LLY).
Alexander Denner, chairman of the CEO search committee, said: “We are excited to welcome Paris as our new chief executive. The search committee conducted an extremely thorough process, and we are very pleased with this outcome. Paris’ track record of global and turnaround success, both strategically and operationally, is just what the company needs at this time.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze